Cutting-Edge Breast Screen Technology Now Available
For the first time, a partnership has made available cutting-edge screening technology for women with breast cancer. Hutt Valley DHB and Volpara, both tech companies, have signed a five-year agreement to accomplish this purpose.
This breast imaging technology was not previously available to members of the public, but the technology has been helping save lives around the world for almost a decade.
For the first time however, this technology has been used around Wellington, the area which Volpara is situated. Women in that area are overjoyed at the presence of such assistance coming to them for the first time from within.
Accordingly, the breast technology helps radiologists to carry out what they call a perfect screening and it also helps work out who needs what imaging according to what their breast tissue is. The team has said that its mission in life is to make the quality of breast cancer screening better globally. Of course, experts are claiming that what is being achieved right brings better outcomes for ladies.
It was reported that this technology had only been present in New Zealand through private healthcare providers, though there claims that it was used extensively overseas. However, this technology has its biggest market in the USA where the technology had been used for several years, with close to two million women as the statistics would have it.
Health experts who make use of the technology have been commending the presence of the service, with a few claiming that it is an arsenal at their disposal to fight disease against women. Hutt Hospital BreastScreen radiologist Jackie Rushton said that having a new tool in her arsenal was invaluable.
It is very much exciting to focus on giving local women access to technology that was not very accessible to them in the past. Now, doctors have different dimension that was not available a few years ago and they can now understand how different compressions affect the film and the details.
In the month of October 2018 alone, Rushton’s department screened over 3000 women, of which 25 were given recalling 127 of those for further images and conducting 41 biopses according to reports.
In October this year, Rushton’s department screened just over 3000 women, recalling 127 of those for further images and conducting 41 biopsies. From the initial 3000 screened, 25 were given a cancer diagnosis.